Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
Date:2/28/2011

CAMBRIDGE, Mass., Feb. 28, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the fourth quarter and year ended December 31, 2010. At December 31, 2010, Idenix's cash and cash equivalents totaled $46.1 million.

Business HighlightsIDX184 Update In February 2011, the U.S. Food and Drug Administration (FDA) removed the full clinical hold for IDX184. The program was placed on partial clinical hold, which allows Idenix to resume clinical trials involving IDX184 immediately. Idenix plans to initiate a Phase IIb 12-week clinical trial of IDX184 in combination with pegylated interferon and ribavirin in the second half of 2011. Under the partial clinical hold, Idenix will share interim data from the Phase IIb study with the FDA.

IDX375, an HCV Non-Nucleoside Polymerase Inhibitor In the first quarter of 2011, Idenix completed a three-day proof-of-concept study of IDX375 in treatment-naïve genotype 1-infected patients. Mean viral load reductions after three days of IDX375 monotherapy were 1.3, 2.3, and 2.7 log(10) IU/mL at doses of 100, 200, and 400 mg BID, respectively. Overall, IDX375 was generally safe and well-tolerated at the three doses tested.

HCV NS5A Inhibitor ProgramIdenix is developing NS5A compounds with pan-genotypic activity. Two drug candidates have been selected for preclinical development, and Idenix plans to file an Investigational New Drug (IND) application or Clinical Trial Application (CTA) for one of these candidates in 2011.

HCV Protease Inhibitor Follow-On ProgramIdenix has discontinued further development of IDX320 following its conclusion that IDX320 likely caused the observed toxicity in the drug-drug interaction (DDI) study with IDX184. I
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals to Hold an Investor/Analyst Day Event on October 30, 2010
2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
5. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
8. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
9. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
10. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
11. Idenix Pharmaceuticals Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 28, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell ... ended June 30, 2015, corporate highlights, and near-term ... are available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment ...
(Date:8/27/2015)... VA (PRWEB) , ... August 27, 2015 , ... ... contractors solve complex business problems, is pleased to announce their ranking as one of ... annual ranking of the fastest-growing private companies across the nation. , “It is truly ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... conferences in the month of September.  ... present at Rodman & Renshaw,s 17th Annual Global Investment ... PT at the St. Regis Hotel in ...
(Date:8/27/2015)... MA (PRWEB) , ... August 27, 2015 , ... Inc. ... United States, ranking iLab Solutions as number 1,361 in growth for the three years ... of the top 0.1% fastest-growing privately held organizations in the country. , “We ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3
... 2009 (EurekAlert)--Advanced Cell Technology, Inc. (OTC:ACTC.PK) and its ... and efficacy of human embryonic stem cell (hESC)-derived ... suitable for human clinical trials. Two important early ... for the treatment of age-related macular degeneration and ...
... Barriers to Care and the Threatening Impact of Diabetes in ... panel of clinical and policy experts gathered by Novo Nordisk ... the exponential growth of diabetes in America. The universal ... the American Diabetes Association (ADA), was that the cost of ...
... AMSTERDAM, June 12 , ... Elsevier today announced a new partnership agreement ... science researchers to,search, discover, and share knowledge locked within ... allows for an,integration of NextBio,s unique set of ontology-based ...
Cached Biology Technology:Assessment of safety and efficacy of human embryonic stem cell therapy 2Assessment of safety and efficacy of human embryonic stem cell therapy 3Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 2Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 3Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 4Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit 5Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 2Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 3Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research 4
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... "swine flu" in 1976 might provide individuals with some ... to new research from St. Jude investigators. Researchers ... mounted an enhanced immune response against both the 2009 ... that circulated during the 2008-09 flu season. The work ...
... Scientists at The University of Nottingham have discovered the gene ... parts after amputation including a whole head and brain. ... piece in the scientific jigsaw that could one day make ... a real possibility. The research led by Dr ...
... CA April 22, 2010 Scientists at The Scripps ... Foundation (GNF) have shed new light on the molecular mechanism ... from a sizzling stove. In addition to contributing to our ... to new therapies for conditions such as acute or chronic ...
Cached Biology News:Study links 1976 'swine flu' shot to stronger immune response to 21st century pandemic flu 2Study links 1976 'swine flu' shot to stronger immune response to 21st century pandemic flu 3Body builders -- the worms that point the way to understanding tissue regeneration 2New Scripps Research and GNF study helps explain how we can sense temperatures 2New Scripps Research and GNF study helps explain how we can sense temperatures 3New Scripps Research and GNF study helps explain how we can sense temperatures 4
Affinity Purified Anti-Human NP-1...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... culture supernates and serum. Each kit contains ... fifteen 96-well plates, provided that the following ...
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Biology Products: